Hepatitis C-vírus-fertőzés: diagnosztika, antivirális terápia, kezelés utáni gondozás. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től.
Abstract
Approximately 70.000 people are infected with hepatitis C virus in Hungary, more than half of whom are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy on one hand. From socioeconomic aspect, this could also prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity. Available since 2003 in...
Source: Orvosi Hetilap - December 15, 2015 Category: Journals (General) Authors: Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Péter Z, Rókusz L, Schneider F, Szalay F, Tornai I, Werling K, Makara M Tags: Orv Hetil Source Type: research
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Conclusions. Grazoprevir and elbasvir with ribavirin for 12 weeks maintained HCV suppression for at least 24 weeks posttherapy without late relapses. Baseline resistance-associated variants (RAVs) stably reappeared at relapse in all 3 patients with virologic failure. NS5A_RAVs emerging at relapse persisted for the full 24-week follow-up period. If confirmed, this finding could complicate retreatment of the small number of patients failing regimens containing an NS5A inhibitor.
Clinical Trials Registration. NCT02105454. (Source: Clinical Infectious Diseases)
Source: Clinical Infectious Diseases - December 14, 2015 Category: Infectious Diseases Authors: Buti, M., Gordon, S. C., Zuckerman, E., Lawitz, E., Calleja, J. L., Hofer, H., Gilbert, C., Palcza, J., Howe, A. Y. M., DiNubile, M. J., Robertson, M. N., Wahl, J., Barr, E., Forns, X. Tags: ARTICLES AND COMMENTARIES Source Type: research
Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy
This study consisted of 171 Japanese patients infected with HCV genotype 1. All 3,266 serum samples taken during and post treatment were tested with both the COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) HCV Test v2.0 and the Abbott RealTime (ART) HCV Test. Of the 2,597 samples undetectable (lower limit of detection [<LOD]) for HCV RNA by the CAP/CTM assay from the on and post treatment, 400 (15.4%) (369 detectable/less than the lower limitation of quantification [<LLOQ] and 31 quantifiable) were detectable by the ART assay. HCV RNA <LOD within the first four weeks by ART was associated with sustained virolog...
Source: Antiviral Therapy - December 13, 2015 Category: Virology Source Type: research
Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
Authors: Vagu C, Sultana C, Ruţă S
Abstract
Improved understanding of the HCV viral life cycle has led to the identification of numerous potential molecular targets for the development of new drugs. Direct acting antivirals -DAAs specifically target a viral encoded protein: the NS3-4A protease, involved in the posttranslational viral protein processing; the NS5B encoded viral polymerase, that conducts the nucleic acid replication and the NS5A encoded phosphoprotein, that participates in both replication and virus assembly. Host-targeted agents, both directed to the early steps of viral replication (recep...
Source: Roumanian Archives of Microbiology and Immunology - December 12, 2015 Category: Microbiology Tags: Roum Arch Microbiol Immunol Source Type: research
Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
This study consisted of 171 Japanese patients infected with HCV genotype 1. All 3,266 serum samples taken during and post treatment were tested with both the COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) HCV Test v2.0 and the Abbott RealTime (ART) HCV Test. Of the 2,597 samples undetectable (lower limit of detection [<LOD]) for HCV RNA by the CAP/CTM assay from the on and post treatment, 400 (15.4%) (369 detectable/less than the lower limitation of quantification [<LLOQ] and 31 quantifiable) were detectable by the ART assay. HCV RNA <LOD within the first four weeks by ART was associated with sustained virological respons...
Source: Antiviral Research - December 12, 2015 Category: Virology Authors: Ogawa E, Furusyo N, Murata M, Hayashi T, Shimizu M, Mukae H, Toyoda K, Hotta T, Uchiumi T, Hayashi J Tags: Antiviral Res Source Type: research
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.Resumen OBJETIVO Comparar los puntajes de Calidad de Vida Relacionada con la Salud (CVRS) en pacientes con hepatitis C crónica sometidos a la terapia antiviral doble y triple y analizar los posibles factores relacionados con la CVRS. MÉTODO La CVRS fue evaluada utilizando el Short Form 36 y elChronic Liver Disease Questionnaire , que fueron aplicados antes y en las semanas 4, 12 y 16 de tratamiento, en 32 pacientes divididos en 2 grupos: terapia doble con interferón...
Source: Revista da Escola de Enfermagem da USP - December 11, 2015 Category: Nursing Source Type: research
Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.
Authors: Stahmeyer JT, Rossol S, Krauth C
Abstract
Hepatitis C is a global public health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Introduction of different direct acting antivirals targeting the hepatitis C proteins has considerably increased rates of sustained viral response. First active substances introduced in 2011 were NS3/4A protease inhibitors telaprevir and boceprevir. In 2013/2014 the second generation of direct acting antivirals sofosbuvir, simeprevir, daclatasvir, ledipasvir and 3D therapy containing ombitasvir/paritaprevir/ritonavir and...
Source: Journal of Comparative Effectiveness Research - December 2, 2015 Category: Journals (General) Tags: J Comp Eff Res Source Type: research
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
CONCLUSION: DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens.
PMID: 26159375 [PubMed - as supplied by publisher] (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 2, 2015 Category: Journals (General) Tags: J Comp Eff Res Source Type: research
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C.
CONCLUSION: VR at week 6, but not at week 4, is an efficient predictor of both SVR and non-SVR to TVR-based triple therapy.
PMID: 26609346 [PubMed - as supplied by publisher] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - November 28, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Direct anti-HCV agents
Publication date: Available online 24 November 2015 Source:Acta Pharmaceutica Sinica B Author(s): Xingquan Zhang Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to sta...
Source: Acta Pharmaceutica Sinica B - November 27, 2015 Category: Cancer & Oncology Source Type: research
Organocatalytic Asymmetric Conjugate Additions to Cyclopent-1-enecarbaldehyde: A Critical Assessment of Organocatalytic Approaches towards the Telaprevir Bicyclic Core.
Abstract
In the context of a programme directed at the manufacture of telaprevir, eight possible approaches to its bicyclic α-amino acid core, based on organocatalytic enantioselective conjugate additions to cyclopent-1-enecarbaldehyde, were identified and preliminarily explored. Four reactions, delivering advanced intermediates en route to the target amino acid, were selected for a thorough optimisation. Three of this reactions involved iminium ion catalysis with a prolinol catalyst (addition of nitromethane, nitroacetate and acetamidomalonate) and one was based on a Cinchona-derived phase-transfer catal...
Source: Chemistry - November 25, 2015 Category: Chemistry Authors: Bernardi L, Fochi M, Carbone R, Martinelli A, Fox ME, Cobley CJ, Kandagatla B, Oruganti S, Dahanukar VH, Carlone A Tags: Chemistry Source Type: research
Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?
Conclusion: In a real-life setting, with a high proportion of cirrhotic and treatment-experienced patients, the overall SVR12 rate was 57.2%. HIV coinfection was not associated with impaired outcome. (Source: European Journal of Gastroenterology and Hepatology)
Source: European Journal of Gastroenterology and Hepatology - November 24, 2015 Category: Gastroenterology Tags: Original Articles: Hepatitis Source Type: research
Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV.
PMID: 26604650 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - November 21, 2015 Category: Gastroenterology Authors: Hartman J, Bichoupan K, Patel N, Chekuri S, Harty A, Dieterich D, Perumalswami P, Branch AD Tags: World J Gastroenterol Source Type: research
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma
Conclusion: The preventive effect of the IFN-free, all-oral regimen of daclatasvir and asunaprevir was observed with a focus on the occurrence and recurrence of HCC, as was IFN-based treatment with telaprevir or simeprevir plus PEG-IFN/RBV.Oncology 2015;89(suppl 2):42-46 (Source: Oncology)
Source: Oncology - November 20, 2015 Category: Cancer & Oncology Source Type: research
Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function.
Authors: Murakami C, Melda Urekli H, Atta MG
Abstract
Over the last decade, treatment options for chronic hepatitis B and hepatitis C infection have markedly evolved. Several Food and Drug Administration-approved drugs are now available for the treatment of chronic hepatitis B, including immunomodulators (standard and pegylated interferon alpha), nucleoside analogues (lamivudine, entecavir and telbivudine) and nucleotide analogues (adefovir dipivoxil and tenofovir). For hepatitis C, the FDA-approved therapies include peginterferon-α, ribavirin, boceprevir, telaprevir, simeprevir and sofosbuvir with expect...
Source: Minerva Gastroenterologica e Dietologica - November 18, 2015 Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research
